Square Pharmaceuticals Limited announced unaudited consolidated earnings results for the second quarter and six months ended December 2017. Consolidated EPS was BDT 3.87 for October-December, 2017 as against BDT 3.33 for October-December, 2016. Consolidated EPS was BDT 7.95 for July-December, 2017 as against BDT 6.62 for July-December, 2016. Consolidated NOCFPS was BDT 8.66 for July-December, 2017 as against BDT 7.94 for July-December, 2016. Consolidated NAV per share was BDT 71.31 as on December 31, 2017 and BDT 66.49 as on June 30, 2017.